Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiotoxicity of R-CHOP vs R-COMP in Diffuse Large B-Cell Lymphoma
NCT00575406Phase 2Completed
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- Dec 2007
- Primary completion
- Jan 2012
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised trial of pegylated liposomal doxorubicin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Primary endpoint: Reduction of cardiotoxicity. Started Dec 2007; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00575406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00575406.